UOSD of Preclinical Models and New Therapeutic Agents Unit - Translational Research Functional Departmental Area
The aim of the Unit is to develop patient-derived models that will set the scene for target identification and for efficacious combination therapy in oncology. Results from the preclinical studies conducted in these models are expected to identify new targeted approaches, able to hamper the malfunctioning signaling network. In particular, the resistance to targeted therapy highlights the need to discover drivers of an early non-mutational drug-tolerance state, before resistance occurs, providing an opportunity for more effective therapeutic approaches. The research topic concerns:
The development of preclinical models “patient-derived” (PD), including primary cultures, tumoroids, circulating tumor cells, PD-xenografts, represents an important platform for the evaluation of new therapeutic agents and for the identification of new biomarkers. This platform (ovarian, lung, colon cancer, melanoma, sarcoma) can represent an opportunity of integration among inter-and intra-department that can reliably disclose the prospective results of clinical practice based on a strong pre-clinical rationale.
Fianco G, Mongiardi MP, Levi A, De Luca T, Desideri M, Trisciuoglio D, Del Bufalo D, Cinà I, Di Benedetto A, Mottolese M, Gentile A, Centonze D, Ferrè F, Barilà D. Caspase-8 contributes to angiogenesis and chemotherapy resistance